TuHURA Biosciences, Inc./NV 8-K

What Happened TuHURA Biosciences, Inc. filed an 8-K on January 30, 2026 reporting that on January 29, 2026 Nasdaq notified the company its consolidated closing bid price had been below $1.00 per share for 35 consecutive business days (as of January 28, 2026), putting it out of compliance with Nasdaq Listing Rule 5550(a)(2). The notice does not trigger immediate delisting; under Nasdaq Listing Rule 5810(c)(3)(A) TuHURA received a 180-calendar day compliance period—until July 28, 2026—to regain compliance by achieving a $1.00+ consolidated closing bid for at least ten consecutive business days.

Key Details

• Consolidated closing bid was below $1.00 for 35 consecutive business days as of January 28, 2026.
• Company has a 180-calendar day cure period ending July 28, 2026 to meet the $1.00 minimum for 10 consecutive business days.
• If not cured, TuHURA may be eligible for a second 180-day period only if it meets market value and other initial listing standards (except the minimum bid) and notifies Nasdaq of intent to cure (potentially via a reverse stock split).
• Failure to regain compliance and ineligibility for extension could lead to delisting unless the company requests a hearing, which would stay any delisting action pending the hearing.

Why It Matters This notice signals a formal listing compliance risk that can affect liquidity, investor confidence and the tradability of TuHURA’s common stock if not remedied. The company must either boost its share price to meet Nasdaq’s minimum bid requirement or pursue measures (such as a reverse split) to regain compliance within the specified timelines. Investors should monitor the company’s share price, any announced corporate actions, and subsequent SEC/Nasdaq filings for developments.